Sheri Rowen, MD
Ophthalmology · Newport Beach, CANPI 1548203904
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.6%), consulting fees and royalties or licence payments — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 28.7% of the total. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,500 payments — averaging $671.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$289K
- Alcon$150K
- Oyster Point Pharma, Inc.$125K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$107K
- Alcon Research LLC$98K
- Rxsight Inc$79K
- plus $160K from 31 others
Across 31 payments — averaging $24,877 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$432K
- Alcon Research LLC$197K
- Novartis$142K
What the payments were for
- Royalty or licence$81,0578%
- Consulting fees$378,20538%
- Speaking & faculty fees$428,96943%
- Travel & lodging$68,3697%
- Food & beverage$51,0415%
- Education$70%
- Entertainment$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$190,627
- MIEBO$182,962
- TYRVAYA$122,253
- TRYPTYR$66,672
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$54,888
- Crystalens Accommodating IOL (AT-52AO)$40,935
- enVista MX60 IOL$40,864
- Oxervate$39,639
- STELLARIS ELITE$38,284
- Trulign IOL$37,535
- PROLENSA$29,614
- ENVISTA TORIC$29,234
- LOTEMAX SM$28,992
- RXSIGHT CONTACT LENS$23,000
- RXSIGHT INJECTOR CARTRIDGE$23,000
- RXSIGHT INJECTOR HANDPIECE$23,000
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$23,000
- LIGHT ADJUSTABLE LENS (LAL)$20,000
- AcrySof IQ PanOptix UV IOL$17,505
- ENVISTA$15,257
How this compares
$1,007,666 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 20 | $997,046 |
| MieboPerfluorohexyloctane/Pf | 60 | $45,338 |
| XiidraLifitegrast | 18 | $28,162 |
| XdemvyLotilaner | 15 | $26,676 |
| ProlensaBromfenac Sodium | 78 | $26,585 |
| Lotemax SmLoteprednol Etabonate | 83 | $20,913 |
| TyrvayaVarenicline Tartrate | 18 | $14,378 |
| BesivanceBesifloxacin Hcl | 38 | $8,281 |
| MoxifloxacinMoxifloxacin Hcl | 153 | $2,959 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $1,651 |
| Prednisolone Acetate | 43 | $1,333 |
| Ketorolac Tromethamine | 18 | $789 |
| Ofloxacin | 27 | $247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $40,594 | $997,04620 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $289,472 | $73,50078 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Besivance | $106,623 | $55,779199 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $5,531 | $26,67615 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $125,233 | $14,37818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Newport Beach
- Ehsan SadriNewport Beach$255K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.